MCID: PRR013
MIFTS: 36

Prurigo Nodularis

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Prurigo Nodularis

MalaCards integrated aliases for Prurigo Nodularis:

Name: Prurigo Nodularis 52 54 71 32
Nodular Prurigo 52

Classifications:



External Ids:

ICD10 32 L28.1
UMLS 71 C0263353

Summaries for Prurigo Nodularis

NIH Rare Diseases : 52 Prurigo nodularis (PN) is a skin disease that causes hard, itchy lumps (nodules ) to form on the skin. The itching (pruritus ) can be intense, causing people to scratch themselves to the point of bleeding or pain. Scratching can cause more skin lesions to appear. The itching is worsened by heat, sweating, or irritation from clothing. In some cases, people with PN have a history of other diseases including eczema (atopic dermatitis ), lymphoma , HIV infection , severe anemia , or kidney disease . The exact cause of PN is unknown. Although scratching is known to cause more nodules to appear, it is unclear what causes the itching to develop in the first place. Diagnosis of the disease is based on observing signs such as extremely itchy skin with the formation of nodules. In some cases, a skin biopsy is used to confirm the diagnosis. Treatment may include corticosteroid creams , oral medications, cryotherapy , or photochemotherapy .

MalaCards based summary : Prurigo Nodularis, also known as nodular prurigo, is related to dermatitis, atopic and allergic hypersensitivity disease. An important gene associated with Prurigo Nodularis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Phospholipase-C Pathway and p70S6K Signaling. The drugs Nalbuphine and Serlopitant have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and tonsil.

Wikipedia : 74 Prurigo nodularis (PN), also known as nodular prurigo, is a skin disease characterised by pruritic... more...

Related Diseases for Prurigo Nodularis

Diseases related to Prurigo Nodularis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 158)
# Related Disease Score Top Affiliating Genes
1 dermatitis, atopic 30.4 TAC1 RNASE3 NGF
2 allergic hypersensitivity disease 30.0 TAC1 RNASE3
3 anhidrosis 30.0 NGFR NGF
4 neuroma 29.8 SEMA3A NGF
5 amyloidosis, primary localized cutaneous, 1 11.4
6 epidermolysis bullosa pruriginosa 11.4
7 amyloidosis, primary localized cutaneous, 2 11.4
8 amyloidosis, primary localized cutaneous, 3 11.4
9 skin disease 10.8
10 dermatitis 10.7
11 neuropathy 10.6
12 peripheral nervous system disease 10.6
13 neurodermatitis 10.5
14 bullous pemphigoid 10.5
15 keratosis 10.4
16 lichen planus 10.4
17 ige responsiveness, atopic 10.4
18 vitiligo-associated multiple autoimmune disease susceptibility 6 10.4
19 vitiligo-associated multiple autoimmune disease susceptibility 1 10.4
20 lymphoma 10.4
21 contact dermatitis 10.4
22 keratoacanthoma 10.4
23 hypereosinophilic syndrome 10.4
24 lymphoma, hodgkin, classic 10.3
25 human immunodeficiency virus type 1 10.3
26 exanthem 10.3
27 hepatitis 10.3
28 allergic contact dermatitis 10.3
29 pustulosis of palm and sole 10.3
30 uremia 10.3
31 chronic kidney disease 10.3
32 scabies 10.3
33 herpes zoster 10.3
34 vasculitis 10.3
35 psoriasis 10.3
36 erythermalgia, primary 10.1
37 hashimoto thyroiditis 10.1
38 systemic lupus erythematosus 10.1
39 pernicious anemia 10.1
40 polykaryocytosis inducer 10.1
41 sarcoidosis 1 10.1
42 thrombocytopenic purpura, autoimmune 10.1
43 celiac disease 1 10.1
44 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.1
45 immune deficiency disease 10.1
46 myeloma, multiple 10.1
47 proteasome-associated autoinflammatory syndrome 1 10.1
48 dermatitis herpetiformis, familial 10.1
49 becker nevus syndrome 10.1
50 lymphoma, non-hodgkin, familial 10.1

Graphical network of the top 20 diseases related to Prurigo Nodularis:



Diseases related to Prurigo Nodularis

Symptoms & Phenotypes for Prurigo Nodularis

Drugs & Therapeutics for Prurigo Nodularis

Drugs for Prurigo Nodularis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 42)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nalbuphine Approved Phase 2, Phase 3 20594-83-6 5311304 5360630
2 Serlopitant Investigational Phase 3 860642-69-9
3 neurokinin A Phase 3
4
Substance P Phase 3 33507-63-0 44359816
5 Neurotransmitter Agents Phase 3
6 Pharmaceutical Solutions Phase 3
7 Narcotics Phase 2, Phase 3
8 Analgesics Phase 2, Phase 3
9 Analgesics, Opioid Phase 2, Phase 3
10 Calcineurin Inhibitors Phase 3
11
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
12
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
13
Pimecrolimus Approved, Investigational Phase 2 137071-32-0 17753757 6447131
14
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
15
Apremilast Approved, Investigational Phase 1, Phase 2 608141-41-9 11561674
16 Immunologic Factors Phase 2
17 Hydrocortisone 17-butyrate 21-propionate Phase 2
18 Hydrocortisone-17-butyrate Phase 2
19 Immunosuppressive Agents Phase 2
20 Hydrocortisone hemisuccinate Phase 2
21 Dermatologic Agents Phase 2
22 Analgesics, Non-Narcotic Phase 1, Phase 2
23 Antirheumatic Agents Phase 1, Phase 2
24 Anti-Inflammatory Agents Phase 1, Phase 2
25 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
26
Citalopram Approved 59729-33-8 2771
27
leucovorin Approved 58-05-9 6006 143
28
Dapsone Approved, Investigational 80-08-0 2955
29
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
30 Antidepressive Agents
31 Serotonin Uptake Inhibitors
32 Psychotropic Drugs
33 Anti-Infective Agents
34 Vitamin B Complex
35 Folic Acid Antagonists
36 Antiprotozoal Agents
37 Folate
38 Antiparasitic Agents
39 Antimalarials
40 Vitamin B9
41 Anti-Bacterial Agents
42
Serotonin Investigational, Nutraceutical 50-67-9 5202

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis Completed NCT03546816 Phase 3 5mg Serlopitant Tablets;Placebo Tablets
2 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis Completed NCT03677401 Phase 3 5mg Serlopitant Tablets;Placebo Tablets
3 A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients Completed NCT02174419 Phase 2, Phase 3 nalbuphine HCl ER tablets 90 mg BID;nalbuphine HCl ER tablets 180 mg BID;Placebo tablets BID
4 An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients Completed NCT02174432 Phase 2, Phase 3 nalbuphine HCl ER 90 mg BID;nalbuphine HCl ER 120 mg BID;nalbuphine HCl ER 180 mg BID
5 A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study) Recruiting NCT03497975 Phase 2, Phase 3 Nalbuphine ER Tablets
6 A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable Recruiting NCT04202679 Phase 3 Dupilumab SAR231893;Placebo;Moisturizers;Low to medium potent topical corticosteroids;Topical calcineurin inhibitors
7 A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable Recruiting NCT04183335 Phase 3 Dupilumab SAR231893;Placebo;Moisturizers;Low to medium potent topical corticosteroids;Topical calcineurin inhibitors
8 A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis Not yet recruiting NCT04204616 Phase 3 Nemolizumab
9 A Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis (PN) Completed NCT03181503 Phase 2 CD14152 Dose A;CD14152 placebo
10 A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist Serlopitant in Subjects With Prurigo Nodularis Completed NCT02196324 Phase 2 serlopitant;Placebo
11 An Open Label, Single Center Study to Assess the Safety and Efficacy of a 24 Week Treatment Course of CC-10004 in Adults With Recalcitrant Nodularis Completed NCT00869089 Phase 2 CC-10004
12 Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease Completed NCT00507832 Phase 2 Pimecrolimus;Hydrocortisone;Pimecrolimus
13 Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis Recruiting NCT03576287 Phase 1, Phase 2 Apremilast Oral Product
14 A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis Active, not recruiting NCT03816891 Phase 2 KPL-716;Placebo
15 Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis Unknown status NCT00532519 citalopram (cipralex)
16 A Double-blind, Randomized, Parallel-group, Side-by-side Single-center Study Comparing a Topical Steroid / Vehicle Combination to a Topical Steroid / Topical Dapsone Combination in Patients With Lichen Simplex Chronicus and/or Prurigo Nodularis Unknown status NCT01870050 Dapsone gel - verum

Search NIH Clinical Center for Prurigo Nodularis

Genetic Tests for Prurigo Nodularis

Anatomical Context for Prurigo Nodularis

MalaCards organs/tissues related to Prurigo Nodularis:

40
Skin, Kidney, Tonsil, T Cells, Brain, Liver, Thyroid

Publications for Prurigo Nodularis

Articles related to Prurigo Nodularis:

(show top 50) (show all 554)
# Title Authors PMID Year
1
Psychiatric disorders and pruritus. 52 61
28511824 2017
2
Treatment of prurigo nodularis with lenalidomide. 52 61
27891738 2017
3
Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin -- an exploration of the cause of neurohyperplasia. 54 61
11875644 2002
4
Eosinophil cationic protein- and eosinophil-derived neurotoxin/eosinophil protein X-immunoreactive eosinophils in prurigo nodularis. 61 54
10994770 2000
5
Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: a reappraisal. 61 54
9609137 1998
6
Eosinophilic cationic protein (ECP) in skin disorders. 61 54
1685831 1991
7
Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. 61
32229281 2020
8
Epidermolysis Bullosa Pruriginosa successfully treated with concomitant topical and systemic agents. 61
32524588 2020
9
Successful treatment of recalcitrant nodular prurigo with tofacitinib. 61
32484964 2020
10
Atopic dermatitis in the elderly Caucasian population: diagnostic clinical criteria and review of the literature. 61
32311089 2020
11
Serum TARC levels before and after treatment for pruritic scabies. 61
32484992 2020
12
New and Emerging Treatments for Inflammatory Itch. 61
32497711 2020
13
Delusional Infestation Can Be a Complication of Prurigo Nodularis with Underlying Neuropathies. 61
32556345 2020
14
Dupilumab as a useful treatment option for prurigo nodularis in an elderly patient with atopic diathesis. 61
32562425 2020
15
Trends in the Demographics and Treatment of Prurigo Nodularis in the United States. 61
32496156 2020
16
The Impact of Prurigo Nodularis on Sleep Disturbance and Related Impact: A Systematic Review. 61
32490566 2020
17
Analysis of 325 Patients with Chronic Nodular Prurigo: Clinics, Burden of Disease and Course of Treatment. 61
32556359 2020
18
Dupilumab for treatment-refractory prurigo nodularis. 61
32469446 2020
19
Safety and Effectiveness of Dupilumab in Prurigo Nodularis. 61
32573461 2020
20
Prevalence of Prurigo Nodularis in the United States. 61
32531481 2020
21
[Clinical characteristics of patients with prurigo nodularis: A descriptive study]. 61
32475624 2020
22
Prevalence of Prurigo Nodularis in Poland. 61
32421199 2020
23
Prurigo Nodularis: Pathogenesis and Management. 61
32461078 2020
24
Cannabinoids for the treatment of chronic pruritus: A review. 61
31987788 2020
25
Racial differences in dermatologic conditions associated with HIV: A cross-sectional study of 4679 patients in an urban tertiary care center. 61
31499147 2020
26
Prurigo Nodularis: Epidemiology and Clinical Features. 61
32454098 2020
27
Prurigo nodularis: New treatments on the horizon. 61
32172924 2020
28
Efficacy of Apremilast in Patients with Prurigo Nodularis: A Proof-of-concept Study. 61
32189005 2020
29
Treatment and Burden of Disease in a Cohort of Patients with Prurigo Nodularis: A Survey-based Study. 61
32215661 2020
30
IL-17A Induces Endothelin-1 Expression through p38 Pathway in Prurigo Nodularis. 61
31476318 2020
31
Chronic prurigo: A retrospective study of 168 cases. 61
31907978 2020
32
Dupilumab for prurigo nodularis: Case series and review of the literature. 61
31917498 2020
33
Association of prurigo nodularis and lichen simplex chronicus with hospitalization for mental health disorders in US adults. 61
32078024 2020
34
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. 61
32074418 2020
35
Nevus sebaceus with syringocystadenoma papilliferum, prurigo nodularis, apocrine cystadenoma, basaloid follicular proliferation, and sebaceoma: case report and review of nevus sebaceus-associated conditions. 61
32239888 2020
36
Implementation of an Ultraviolet Phototherapy Service at a National Referral Hospital in Western Kenya: Reflections on Challenges and Lessons Learned. 61
31734938 2020
37
Diagnostic and treatment algorithm for chronic nodular prurigo. 61
31310842 2020
38
Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study. 61
32078192 2020
39
Real-World Prevalence of Prurigo Nodularis and Burden of Associated Diseases. 61
31421126 2020
40
Healthcare resource utilization and payer cost analysis of patients with prurigo nodularis. 61
32017045 2020
41
Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients. 61
31529718 2020
42
Response: Management challenges in prurigo nodularis. 61
32068455 2020
43
Breaking the Itch-Scratch Cycle in Prurigo Nodularis. 61
32074425 2020
44
Efficacy of dupilumab in prurigo nodularis in elderly patient. 61
31856368 2020
45
An observational analysis of low-dose thalidomide in recalcitrant prurigo nodularis. 61
31132160 2020
46
Emerging novel therapeutic agents for the treatment of patients with prurigo nodularis. 61
31900001 2020
47
Analysis of real-world treatment patterns in patients with prurigo nodularis. 61
31521720 2020
48
Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Phenotype of Adult Atopic Dermatitis. 61
31517666 2020
49
[THREE CASES OF ATOPIC DERMATITIS CHILDREN WITH INTRACTABLE PRURIGO NODULARIS]. 61
32435023 2020
50
Association between Prurigo Nodularis and Etiologies of Peripheral Neuropathy: Suggesting a Role for Neural Dysregulation in Pathogenesis. 61
31936197 2020

Variations for Prurigo Nodularis

Expression for Prurigo Nodularis

Search GEO for disease gene expression data for Prurigo Nodularis.

Pathways for Prurigo Nodularis

Pathways related to Prurigo Nodularis according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.55 SEMA3A NGFR NGF
2
Show member pathways
12.52 SEMA3A NGFR NGF
3
Show member pathways
12.05 SEMA3A NGFR NGF
4 11.65 NGFR NGF
5
Show member pathways
11.54 SEMA3A NGFR NGF
6
Show member pathways
11.35 NGFR NGF
7
Show member pathways
11.27 NGFR NGF
8
Show member pathways
11.19 NGFR NGF
9
Show member pathways
11.11 NGFR NGF
10 10.87 SEMA3A NGFR NGF
11 10.46 NGFR NGF

GO Terms for Prurigo Nodularis

Cellular components related to Prurigo Nodularis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.46 TAC1 SEMA3A RNASE3 NGF
2 axon GO:0030424 9.13 TAC1 SEMA3A NGF
3 extracellular region GO:0005576 9.02 TAC1 SEMA3A RNASE3 NGFR NGF

Biological processes related to Prurigo Nodularis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.37 NGF NGFR
2 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.32 NGF NGFR
3 positive regulation of axonogenesis GO:0050772 9.26 NGFR NGF
4 neurotrophin TRK receptor signaling pathway GO:0048011 9.16 NGFR NGF
5 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 8.96 NGFR NGF
6 nerve development GO:0021675 8.8 SEMA3A NGFR NGF

Sources for Prurigo Nodularis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....